Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Rivière I, Larson SM, Koutcher JA, Sadelain M. Gade TP, et al. Among authors: osborne jr. Cancer Res. 2005 Oct 1;65(19):9080-8. doi: 10.1158/0008-5472.CAN-05-0436. Cancer Res. 2005. PMID: 16204083
A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.
Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS. Osborne JR, et al. J Urol. 2014 May;191(5):1439-45. doi: 10.1016/j.juro.2013.10.041. Epub 2013 Oct 14. J Urol. 2014. PMID: 24135437 Free PMC article.
Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM. Cheal SM, et al. Among authors: osborne jr. Eur J Nucl Med Mol Imaging. 2014 May;41(5):985-94. doi: 10.1007/s00259-013-2679-1. Epub 2014 Mar 7. Eur J Nucl Med Mol Imaging. 2014. PMID: 24604591 Free PMC article.
Utility of FDG-PET in clinical neuroendocrine prostate cancer.
Spratt DE, Gavane S, Tarlinton L, Fareedy SB, Doran MG, Zelefsky MJ, Osborne JR. Spratt DE, et al. Among authors: osborne jr. Prostate. 2014 Aug;74(11):1153-9. doi: 10.1002/pros.22831. Epub 2014 Jun 9. Prostate. 2014. PMID: 24913988 Free PMC article.
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. Pandit-Taskar N, et al. Among authors: osborne jr. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21. Eur J Nucl Med Mol Imaging. 2014. PMID: 25143071 Free PMC article. Clinical Trial.
Disparities in castration-resistant prostate cancer trials.
Spratt DE, Osborne JR. Spratt DE, et al. Among authors: osborne jr. J Clin Oncol. 2015 Apr 1;33(10):1101-3. doi: 10.1200/JCO.2014.58.1751. Epub 2015 Feb 17. J Clin Oncol. 2015. PMID: 25691679 Free PMC article. No abstract available.
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gönen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ. Pandit-Taskar N, et al. Among authors: osborne jr. Clin Cancer Res. 2015 Dec 1;21(23):5277-85. doi: 10.1158/1078-0432.CCR-15-0552. Epub 2015 Jul 14. Clin Cancer Res. 2015. PMID: 26175541 Free PMC article. Clinical Trial.
213 results